Search clinical trials for: RLX030

Total 15 results

Novartis Pharmaceuticals

Completed

Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure (RELAX-REPEAT)

Chronic Heart Failure

Germany, United States, Spain, Italy, Norway, Netherlands, Turkey, Russian Federation, Sweden, Finland, Czech Republic, Romania, Australia
Novartis Pharmaceuticals

Terminated

Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure (RELAX-Cardio)

Chronic Heart Failure

Germany, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure

Acute Heart Failure

Netherlands, Germany, Italy, Argentina, Russian Federation, Poland
Novartis Pharmaceuticals

Completed

Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)

Chronic Heart Failure (CHF)

Netherlands, Germany, Poland, United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects

Hepatic Impairment

Germany, Russian Federation
Novartis Pharmaceuticals

Completed

PK of Serelaxin in Severe Renal Impairment and ESRD (CRLX030A2102)

End-Stage Renal Disease | Renal Failure, Chronic

Germany
Novartis Pharmaceuticals

Terminated

Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure (RELAX-PEDS-PK)

Acute Heart Failure

United States, Germany, United Kingdom, Switzerland
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia

Pre-eclampsia

Italy, United States
Novartis Pharmaceuticals

Terminated

Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients (RELAX-AHF-EU)

Acute Heart Failure (AHF)

Germany, Belgium, Croatia, Estonia, Hungary, Lithuania, Russian Federation, Austria, Switzerland, Spain, France, Greece, Slovenia, Bulgaria, Czechia, Italy, Serbia, Finland, United Kingdom, Poland, Portugal, Romania, Latvia, Slovakia, I...
University of Edinburgh
Novartis Pharmaceuticals; NHS Lothian

Completed

Serelaxin To Lower Portal Pressure (STOPP)

Liver Cirrhosis | Hypertension, Portal

United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF (RELAX-AHF-2)

Acute Heart Failure

Germany, United States, Colombia, Romania, South Africa, Italy, Austria, Belgium, Czechia, Hungary, Turkey, United Kingdom, Switzerland, Australia, France, Israel, Netherlands, Sweden, Spain, Argentina, Bulgaria, Ireland, Denmark, Mexico and more
Novartis Pharmaceuticals

Terminated

Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF (RELAX-AHF-ASIA)

Acute Heart Failure

India, Taiwan, Japan, Korea, Republic of, Thailand, Lebanon, Philippines, China, Malaysia, Singapore, Jordan
Novartis Pharmaceuticals

Completed

An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension

Compensated Cirrhosis and Portal Hypertension

United Kingdom
Novartis Pharmaceuticals

Completed

Study of the Vascular Effects of Serelaxin

Coronary Artery Disease

United Kingdom
Corthera, Inc.(formerly BAS Medical, Inc.), a member...

Terminated

Recombinant Human Relaxin for the Treatment of Decompensated CHF

Congestive Heart Failure (CHF)

Russian Federation

Search clinical trials for: RLX030

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations